Eltrombopag/Eltrombopag Zhengda Tianqing

Chia Tai Tianqing is a company that produces domestic generic drugs of Eltrombopag (Eltrombopag). Eltrombopag is an oral, small molecule, non-peptide thrombopoietin receptor agonist (TPO-RA) used primarily to treat patients with chronic immune (idiopathic) thrombocytopenia (ITP) to help increase platelet counts and reduce or prevent bleeding.

Chia Tai Tianqing Pharmaceutical is a well-known pharmaceutical company focusing on the research and development, production and sales of drugs. According to relevant information, Chia Tai Tianqing has successfully developed and produced Eltrombopag ethanolamine tablets and obtained approval for marketing from the National Medical Products Administration. The trade name of this drug is "Taprosin", and its approved indications are for adults and children aged 6 and above with chronic immune (idiopathic) thrombocytopenia (ITP) who have failed to respond to previous treatments such as glucocorticoids and immunoglobulins.

In addition to Zhengda Tianqing, other companies are also producing Eltrombopag, including the original pharmaceutical manufacturer GlaxoSmithKline (GSK) of the United Kingdom and Novartis of Switzerland. In addition, some domestic pharmaceutical companies such as Qilu Pharmaceutical and Kelun Pharmaceutical also produce domestic generic versions of Eltrombopag.

It should be noted that different brands of Eltrombopag products may have some differences, such as dosage, side effects, price, etc. Therefore, when using eltrombopag, patients should follow their doctor's advice, choose the brand and dosage that suits them, and pay close attention to any possible side effects.

Overall, eltrombopag is an important drug with an important role in the treatment of diseases such as chronic immune thrombocytopenia. As one of the manufacturers, Zhengda Tianqing provides patients with more choices. When using eltrombopag, patients should fully understand the nature and usage of the drug to ensure its effectiveness and safety.